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ES-62, a glycoprotein secreted by the ﬁlarial nematode Acanthocheilonema viteae, exhibits anti-
inﬂammatory properties by virtue of covalently attached phosphorylcholine moieties. Screening of a
library of ES-62 phosphorylcholine-based small molecule analogues (SMAs) revealed that two com-
pounds, termed 11a and 12b, mirrored the helminth product both in inhibiting mast cell degranulation
and cytokine responses in vitro and in preventing ovalbumin-induced Th2-associated airway inﬂamma-
tion and eosinophil inﬁltration of the lungs in mice. Furthermore, the two SMAs inhibited neutrophil
inﬁltration of the lungs when administered therapeutically. ES-62-SMAs 11a and 12b thus represent
starting points for novel drug development for allergies such as asthma.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Asthma is a chronic ailment of the lungs associated with airway nema viteae (Harnett et al., 1989), can directly interfere with
inﬂammation and exaggerated responses to infections, allergens
and irritants that has shown a clear increase in occurrence in Wes-
tern countries in recent decades. For example, asthma incidence
rose in the USA from 7.3% in 2001 to 8.4% in 2010 such that the
number of people afﬂicted reached 25.7 million, with prevalence
highest in children (Akinbami et al., 2012). However, such an
increase has not been mirrored in rural areas of the Third World
where parasitic worms are highly abundant (see Keiser and
Utzinger, 2010) and this has led to the suggestion that such patho-
gens may protect humans from developing asthma. Although the
situation is not clear-cut and may be inﬂuenced by factors such
as the species of helminth under study, there is sufﬁcient support-
ive evidence for this idea to possess some merit (reviewed by
Cooper, 2009). Furthermore, an increasing body of data exists to
show that parasitic worms or their secreted products can prevent
the development of allergic conditions in the lungs in mouse mod-
els (reviewed by Danilowicz-Luebert et al., 2011). One such
secreted product, ES-62, a phosphorylcholine (PC)-containing gly-
coprotein derived from the rodent ﬁlarial nematode Acanthocheilo-allergic responses by blocking mast cell activation via the high
afﬁnity IgE receptor, FceRI, thereby preventing release of inﬂam-
matory mediators (Melendez et al., 2007; Ball et al., 2013). How-
ever, as shown in a mouse model of ovalbumin (OVA)-induced
airway hyper-reactivity (OAH), it is also able to prevent disease
by reversing the Th2 cell polarity that contributes to allergy
(Melendez et al., 2007; Rzepecka et al., 2013). These data suggest
that ES-62 could exhibit therapeutic potential in human asthma
but it is a large and hence potentially immunogenic molecule
and thus in theory is likely to be unsuitable for use as a drug. For
this reason, we decided to investigate a recently prepared library
of drug-like small molecule analogues (SMAs) of ES-62 (Al-
Riyami et al., 2013). These focus on the PC moiety of the helminth
product, as we have previously shown this to be responsible for
many of its anti-inﬂammatory activities (Harnett et al., 2008).
We ﬁrst investigated in vitro mast cell responses. FceRI-medi-
ated mast cell activation (degranulation and cytokine secretion)
is dependent on the mobilization of intracellular calcium
(Gilﬁllan and Beaven, 2011; Wu, 2011; MacGlashan, 2012) and
consistent with this, we have previously shown that the ES-62-
mediated desensitisation of such mast cell function is associated
with suppression of calcium signalling in human bone marrow-
derived mast cells (BMMCs) and mouse peritoneal-derived mast
cells (PDMCs) (Melendez et al., 2007; Ball et al., 2013). We there-
Fig. 1. Small molecule analogues (SMAs) 11a and 12b of the immunomodulatory helminth product ES-62 inhibit mast cell calcium mobilisation, degranulation and cytokine
production. (A, B) Structures of 11a and 12b and their effects on high afﬁnity IgE receptor (FceRI)-mediated calcium mobilisation. Measurement of calcium mobilisation was
undertaken as previously described (Ball et al., 2013). Mouse bone marrow-derived mast cells were sensitised with murine anti-DNP IgE (0.5 lg/ml) in the presence and
absence of SMA 11a or 12b (5 lg/ml) overnight at 37 C. Following loading with Fura-2-acetyoxymethyl ester (Fura-2AM), the cells were stimulated at the 50 s time-point
with DNP (0.5 lg/ml) to induce cross-linking (XL) of FceR1 and intracellular calciummobilisation and inﬂux was then recorded in real time using excitation-emission ratios of
340/380 nm. Data are presented as the mean calcium values of triplicate samples and ⁄⁄⁄P < 0.001 by ANOVA and Newman–Keuls multiple comparison test. (C, D) Peritoneal-
derived mast cells and (E–H) Bone marrow-derived mast cells were pre-treated with the indicated concentrations of 11a and 12b (1, 2 or 5 lg/ml) during the IgE sensitisation
phase and then degranulation was measured by release of b-hexosaminidase as described previously (Melendez et al., 2007; Ball et al., 2013) 1 h following crosslinking of the
IgE-bound FceRI (XL) or not (C, D). (E, F) TNFa and (G, H) IL-6 release were measured by ELISA as described previously (Melendez et al., 2007; Ball et al., 2013) 24 h following
crosslinking. Data are presented as means ± S.D. where n = 3 and analysis is by one-way ANOVA and Newman–Keuls post test where ⁄⁄⁄P < 0.001. All data are representative of
at least three independent experiments.
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Fig. 2. Small molecule analogues (SMAs) 11a and 12b of the immunomodulatory helminth product ES-62 induce Protein Kinase C alpha (PKCa) down-regulation in mouse
bone marrow-derived mast cells (BMMCs). PKCa expression was measured by laser scanning cytometry (LSC) as described previously (McGrath et al., 2011). BMMCs were
sensitised with anti-DNP-IgE overnight in the presence of 1 lg/ml of BSA, phosphorylcholine (PC)-BSA, SMA 11a or SMA 12b prior to ﬁxing, permeabilising and staining of
PKCa expression using anti-mouse PKCa antibody. (A) Exemplar plots of the gating strategy for quantitative analysis of BMMCs (gated on DAPI staining of their nuclei) for
PKCa expression mean ﬂuorescence integral (MFI) relative to an IgG2a isotype control. (B) The relocation feature of the LSC generates representative images (40) of PKCa
(Alexa 488; green) expression by BMMCs from each treatment group, counterstained with DAPI (blue) to identify the cell nucleus. Images were captured using a Hamamatsu
Orca ER digital camera and the OpenLab 3.0.9 digital imaging program (Improvision). (C) Analysis by Wincyte software of at least 2000 BMMCs under each treatment
condition allowed quantitation of the percentage of PKCa+ BMMCs in each group, the MFI value of PKCa expression by BMMCs and the maximum (max) pixel value of PKCa
expression by BMMCs.
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of calcium mobilization as a screen for testing the ability of ES-
62 SMAs (65 in total) to similarly desensitise mouse BMMC
responses. Only a small number of the compounds showed any evi-
dence of being able to suppress FceRI-mediated calcium mobiliza-
tion, with the sulfones 11a and 12b (Fig. 1A and B), which reduced
mobilization to 66.4 ± 3.5% and 62.6 ± 5.5% (mean ± S.E.M.) of the
control value, respectively (Fig. 1A and B), being most effective.
These two SMAs were therefore selected for further analysis as
possible anti-allergy ES-62 mimics; of note, we had previously
shown one of them - 11a - to prevent development of collagen-
induced arthritis (CIA) in mice (Al-Riyami et al., 2013).
Continuing with mast cells, 11a and 12b were ﬁrst tested for
their ability to inhibit degranulation of these cells when activated
via FceRI. We have recently shown (Ball et al., 2013) that whilst
mouse BMMCs produce high levels of eicosanoids, cytokines and
chemokines, they make poor degranulation responses to activation
via FceRI. By contrast, PDMCs respond strongly in terms of degran-
ulation, but not cytokine production, following stimulation with
antigen, whilst bone marrow-derived connective tissue type mast
cells (CTMCs) display an intermediate phenotype. Importantly,
ES-62 was able to desensitise FceRI-signalling in all of these mast
cell subsets (Ball et al., 2013). Due to their strong degranulation
reaction, PDMCs were employed to test the effects of 11a and
12b on this mast cell response, mediated via FceRI ligation and
crosslinking, and both were found to be able to inhibit it (Fig. 1Cand D). Similar results were obtained with the rat basophilic leu-
kaemia cell line RBL-2H3 (results not shown). 11a and 12b were
next tested for their ability to mimic ES-62 in inhibiting the TNFa
(Fig. 1E and F) and IL-6 (Fig. 1G and H) responses of BMMCs acti-
vated via FceRI (Ball et al., 2013). Both SMAs were found to inhibit
secretion of these cytokines and in a dose-dependent manner.
ES-62-mediated inhibition of human BMMC responses is associ-
ated with degradation of protein kinase C alpha (PKCa) (Melendez
et al., 2007) and subsequent uncoupling of FceRI from phospholi-
pase D (PLD) and sphingosine kinase (SphK), signals that have been
shown to be important in calcium mobilization and degranulation
in mast cells (Gilﬁllan and Beaven, 2011; Spiegel and Milstien,
2011). Similarly, we have shown ES-62-mediated desensitisation
of mouse PDMC, BMMC and CTMC degranulation and/or cytokine
release to be associated with PKCa degradation (Ball et al., 2013).
Thus, to determine whether SMAs 11a and 12b were mimicking
this mechanism of action of ES-62, we investigated the effect of
these SMAs on PKCa expression using quantitative laser-scanning
cytometry (Harnett, 2007). PC conjugated to BSA was used as a
positive control (and compared with BSA) for this experiment
due to the ability of PC-conjugates such as this to mimic immuno-
modulation by ES-62 (Harnett et al., 2008; Al-Riyami et al., 2013)
and as shown in Fig. 2, both SMAs mirrored PC-BSA in down-regu-
lating expression of PKCa in mouse BMMCs. This was evident not
only in the percentage of mast cells positive for PKCa, but also in
a reduction of the levels of PKCa expression (mean ﬂuorescence
Fig. 3. Small molecule analogues (SMAs) 11a and 12b of the immunomodulatory helminth product ES-62 suppress ovalbumin (OVA)-induced airway hyper-responsiveness
(OAH). BALB/c mice undergoing OAH (OVA) were treated with SMAs 11a (1 or 10 lg/dose) or 12b (1 or 10 lg/dose) either prophylactically (s.c.; A–G) as described in
Supplementary Fig. S1A and previously (Rzepecka et al., 2013) or therapeutically (intra-nasal; H–K) where mice only received SMAs 1 h before OVA challenge on days 25, 26
and 27 of the experiment as described in Supplementary Fig. S1B. Mice were assessed at sacriﬁce via bronchoalveolar lavage for lung eosinophil (A, B) or neutrophil
inﬁltration (C, H, I) and lung pathology as indicated by H & E staining from two independent models (D and E; PBS represents control mice). In A–C, data are pooled from three
independent experiments and for H and I, data are pooled from four independent experiments. Analysis of IL-4 (F), IL-17 (G) IL-13 (J) and IFNc (K) mRNA levels in the lungs
from the various treatment groups from a single prophylactic (F, G) or therapeutic (J, K) experiment are shown. Real time quantitative Reverse Transcription-PCR procedures
were carried out as described previously (Rzepecka et al., 2013) and according to the manufacturer’s instructions (Applied Biosystems, Carlsbad CA, USA) using assay kits, Mm
00445259_m1 (IL-4), Mm00439619_m1 (IL-17), Mm00434204_m1 (IL-13), Mm 01168134_ml (IFNc) and Mm 99999915_g1 (GAPDH). All samples were examined in
triplicate and data analysed by StepOne software using the comparative CT (DDCT) (Applied Biosystems) with values for samples being normalised to the reference reporter
GAPDH. All data represent responses from individual mice in the indicated groups. Where relevant, analysis was by one-way ANOVA using Bonferroni’s post test; ⁄P < 0.05,
⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001, respectively. All procedures were conducted in accordance with home ofﬁce UK animal guidelines and with the approval of the local ethical
committees.
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pixel). The last result suggested that the residual low levels of
expression observed in PC-BSA or SMA-treated cells reﬂect a dis-
persed distribution throughout the cells, rather than translocation
and association in foci with membranes, which would be indicative
of activation.
SMAs 11a and 12b were next tested for their ability to mimic
ES-62 in an in vivo situation, speciﬁcally in demonstrating protec-
tion against allergic responses in the lungs of mice sensitised and
challenged with OVA in a prophylactic model (Melendez et al.,
2007; Rzepecka et al., 2013). This model (Supplementary
Fig. S1A) gives signiﬁcant cell inﬁltration and a strong inﬂamma-
tory response in the lungs during antigen challenge (Patel et al.,
2005), and involves targeting of both the sensitization and chal-
lenge phases by the SMAs. Although we have previously reported
that ES-62 inhibits mast cell degranulation in the lungs in this
model (Melendez et al., 2007), the number of mast cells detectable
in the bronchoalveolar lavage (BAL) is relatively very small and
thus we focused on an alternative approach to assessing an anti-
allergy effect, speciﬁcally on measuring the levels of more abun-
dant inﬂammatory cell types that inﬁltrate the lungs during OVA
challenge. Thus, as can be seen in Fig 3 the two SMAs successfully
reduced eosinophil inﬁltration both in terms of the proportion
(Fig. 3A) and absolute numbers (Fig. 3B) of cells as measured by
BAL. Effects on neutrophils were less obvious, e.g., inhibition of
neutrophil numbers (Fig. 3C) only reached statistical signiﬁcance
with SMA 12b employed at a 1 lg dose. No signiﬁcant effect could
be found on either macrophage or lymphocyte inﬁltration via BAL
(results not shown). The protective effects of 11a and 12b were
conﬁrmed by histological analysis of H & E staining (Fig. 3D and
E) and were corroborated by ﬁndings that, similar to ES-62
(Rzepecka et al., 2013), both SMAs reduced the mRNA levels of
IL-4 (Fig. 3F) and IL-17 (Fig. 3G) which act to drive pathogenic
Th2 responses in the lungs (Iwakura et al., 2011; Dias and
Banerjee, 2012). The suppression of IL-17 is perhaps surprising in
the context of the observed relatively weak inhibitory effect of
the two SMAs on neutrophil inﬂux of the lungs, given the role
played by this cytokine in neutrophil recruitment (Ye et al.,
2001), but the data may simply indicate that the levels of neutro-
phils in the lungs are not solely dependent on local levels of IL-17.
At the same time, its targeting may reﬂect the important role of IL-
17 in driving eosinophilic inﬂammation, including in asthma
(Iwakura et al., 2011; Dias and Banerjee, 2012).
Finally, we also employed a therapeutic model (Supplementary
Fig. S1B) of airway hyper-reactivity (Patel et al., 2005), which is
more relevant to the clinical situation, e.g., in treating asthma exac-
erbations. In this OVA-based model, SMAs 11a and 12b showed
evidence of inhibiting both the proportion (Fig. 3H) and absolute
numbers (Fig. 3I) of neutrophils, but not eosinophils (results not
shown) in the BAL. We also measured the levels of IL-4 and IL-17
mRNA in the lungs in this therapeutic model but although there
was a tendency towards a reduction with respect to IL-4, no statis-
tically signiﬁcant changes were observed with either cytokine
when mice were exposed to the two SMAs (results not shown).
Again, the result obtained with IL-17 is more indicative of a corre-
lation between local levels of this cytokine and eosinophil, rather
than neutrophil, inﬁltration whilst the lack of a statistically signif-
icant reduction with regards to IL-4 in this therapeutic model may
possibly reﬂect the Th2 polarisation existing prior to administra-
tion of the SMAs. Nevertheless, a statistically signiﬁcant reduction
in mRNA for IL-13 (Fig. 3J), another Th2 cytokine known to play a
key role in asthma pathogenesis (Wills-Karp, 2004), was observed
when a 10 lg dose of SMA 11a or 12b was employed. Furthermore,
this inversely correlated with an increase in mRNA for the Th1-
associated cytokine IFNc (Fig. 3K) therefore indicating that the
two SMAs were showing some evidence of mimicking ES-62(Rzepecka et al., 2013) in reversing the polarity of the Th cell
response.
Several parasitic nematode products, in addition to ES-62,
including ﬁlarial nematode cystatin (Schnoeller et al., 2008) and
a MIF homologue from Anisakis simplex (Park et al., 2009), have
been reported to be active in protecting against OVA-induced air-
way hypersensitivity in mouse models. However as alluded to ear-
lier, one potential problem in exploiting such immunomodulators
for use in the clinic is their potential immunogenicity. In the case
of ES-62, the active anti-inﬂammatory moiety is a nematode-spe-
ciﬁc post-translational modiﬁcation (Harnett et al., 2008; Al-
Riyami et al., 2013) and therefore this provided an opportunity
to explore a small molecule mimetic approach. By taking this
opportunity, we have now provided proof-of-principle that drug-
like SMAs of a helminth product with anti-allergy properties can
be designed. Furthermore, we have shown not only that these com-
pounds mimic the parent molecule in offering protection in a pro-
phylactic model of airway hyperresponsiveness, but that they can
also be successfully employed in a therapeutic model. This
strengthens the idea that ES-62-based SMAs represent a starting
point in novel drug development for the treatment of asthma.
The inhibitory effect on neutrophils observed in the therapeutic
model is particularly interesting given the role played by these
cells in chronic, steroid-resistant asthma, which is often very difﬁ-
cult to treat and where there is a clear unmet clinical need.
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